1. Home
  2. BCDA vs WTO Comparison

BCDA vs WTO Comparison

Compare BCDA & WTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • WTO
  • Stock Information
  • Founded
  • BCDA N/A
  • WTO 2008
  • Country
  • BCDA United States
  • WTO China
  • Employees
  • BCDA N/A
  • WTO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • WTO Consumer Electronics/Appliances
  • Sector
  • BCDA Health Care
  • WTO Technology
  • Exchange
  • BCDA Nasdaq
  • WTO Nasdaq
  • Market Cap
  • BCDA 7.9M
  • WTO 8.0M
  • IPO Year
  • BCDA N/A
  • WTO 2021
  • Fundamental
  • Price
  • BCDA $2.54
  • WTO $0.27
  • Analyst Decision
  • BCDA Strong Buy
  • WTO
  • Analyst Count
  • BCDA 1
  • WTO 0
  • Target Price
  • BCDA $25.00
  • WTO N/A
  • AVG Volume (30 Days)
  • BCDA 59.9K
  • WTO 482.7K
  • Earning Date
  • BCDA 03-26-2025
  • WTO 02-24-2025
  • Dividend Yield
  • BCDA N/A
  • WTO N/A
  • EPS Growth
  • BCDA N/A
  • WTO N/A
  • EPS
  • BCDA N/A
  • WTO N/A
  • Revenue
  • BCDA $71,000.00
  • WTO $32,309,502.00
  • Revenue This Year
  • BCDA N/A
  • WTO N/A
  • Revenue Next Year
  • BCDA N/A
  • WTO N/A
  • P/E Ratio
  • BCDA N/A
  • WTO N/A
  • Revenue Growth
  • BCDA N/A
  • WTO 47.36
  • 52 Week Low
  • BCDA $1.63
  • WTO $0.25
  • 52 Week High
  • BCDA $8.85
  • WTO $62.25
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 53.10
  • WTO 43.18
  • Support Level
  • BCDA $2.27
  • WTO $0.27
  • Resistance Level
  • BCDA $2.95
  • WTO $0.30
  • Average True Range (ATR)
  • BCDA 0.25
  • WTO 0.02
  • MACD
  • BCDA 0.02
  • WTO 0.00
  • Stochastic Oscillator
  • BCDA 48.19
  • WTO 42.86

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About WTO UTime Limited

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; and Do, as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

Share on Social Networks: